Warning: The NCBI web site requires JavaScript to function. more...
NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T, Hoshino M, Aoki K, Ohya K, Komano Y, Nanki T, Miyasaka N, Umezawa K.
Arthritis Res Ther. 2007;9(5):R97.
Related citations
Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.
J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.
Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH.
Mol Pharmacol. 2010 Jan;77(1):17-25. Epub 2009 Oct 14.
Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T.
Arthritis Res Ther. 2005;7(6):R1348-59. Epub 2005 Sep 30.
Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor.
Kaneda T, Nojima T, Nakagawa M, Ogasawara A, Kaneko H, Sato T, Mano H, Kumegawa M, Hakeda Y.
J Immunol. 2000 Oct 15;165(8):4254-63.
NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.
Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF.
J Biol Chem. 2007 Jun 22;282(25):18245-53. Epub 2007 May 7.
IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance.
Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB.
J Immunol. 2003 Mar 1;170(5):2655-62.
Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M.
Life Sci. 2007 Mar 13;80(14):1311-8. Epub 2007 Jan 23.
Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.
J Cell Physiol. 2009 Dec;221(3):618-28.
Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.
J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.
Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.
Bone. 2007 Oct;41(4):592-602. Epub 2007 Jun 13.
Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
Bharti AC, Takada Y, Aggarwal BB.
J Immunol. 2004 May 15;172(10):5940-7.
Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
Tsuji-Naito K.
Bioorg Med Chem. 2008 Oct 15;16(20):9176-83. Epub 2008 Sep 14.
Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.
Biochem Biophys Res Commun. 2005 Apr 15;329(3):839-45.
IL-23 induces receptor activator of NF-kappaB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-kappaB signal pathways.
Li X, Kim KW, Cho ML, Ju JH, Kang CM, Oh HJ, Min JK, Lee SH, Park SH, Kim HY.
Immunol Lett. 2010 Jan 4;127(2):100-7. Epub 2009 Nov 10.
Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.
Ichikawa H, Aggarwal BB.
Clin Cancer Res. 2006 Jan 15;12(2):662-8.
Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis.
Lubberts E, Oppers-Walgreen B, Pettit AR, Van Den Bersselaar L, Joosten LA, Goldring SR, Gravallese EM, Van Den Berg WB.
Arthritis Rheum. 2002 Nov;46(11):3055-64.
Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.
Grcević D, Lukić IK, Kovacić N, Ivcević S, Katavić V, Marusić A.
Clin Exp Immunol. 2006 Oct;146(1):146-58.
The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, Nakagawa T, Löeffler M, Kodama T, Kurosawa H, Taniguchi T.
Arthritis Rheum. 2004 Mar;50(3):794-804.
Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos.
Ha J, Choi HS, Lee Y, Lee ZH, Kim HH.
Int Immunopharmacol. 2009 Jun;9(6):774-80. Epub 2009 Mar 12.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on